Cytek Biosciences Inc

NASDAQ:CTKB USA Medical Devices
Market Cap
$546.34 Million
Market Cap Rank
#10931 Global
#4973 in USA
Share Price
$4.25
Change (1 day)
+2.91%
52-Week Range
$2.42 - $5.88
All Time High
$27.93
About

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more

Cytek Biosciences Inc (CTKB) - Total Liabilities

Latest total liabilities as of December 2025: $119.80 Million USD

Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has total liabilities worth $119.80 Million USD as of December 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cytek Biosciences Inc - Total Liabilities Trend (2019–2025)

This chart illustrates how Cytek Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Cytek Biosciences Inc Competitors by Total Liabilities

The table below lists competitors of Cytek Biosciences Inc ranked by their total liabilities.

Liability Composition Analysis (2019–2025)

This chart breaks down Cytek Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.04 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.35 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.26 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cytek Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cytek Biosciences Inc (2019–2025)

The table below shows the annual total liabilities of Cytek Biosciences Inc from 2019 to 2025.

Year Total Liabilities Change
2025-12-31 $119.80 Million +15.46%
2024-12-31 $103.76 Million +2.34%
2023-12-31 $101.39 Million +7.95%
2022-12-31 $93.93 Million +62.17%
2021-12-31 $57.92 Million -75.46%
2020-12-31 $236.01 Million +110.60%
2019-12-31 $112.06 Million --